Royce & Associates LP Reduces Stock Holdings in Artivion, Inc. (NYSE:AORT)

Royce & Associates LP reduced its stake in shares of Artivion, Inc. (NYSE:AORT) by 13.3% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 871,170 shares of the company’s stock after selling 133,210 shares during the quarter. Royce & Associates LP’s holdings in Artivion were worth $23,191,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the stock. Creative Planning raised its holdings in shares of Artivion by 182.1% during the 3rd quarter. Creative Planning now owns 28,635 shares of the company’s stock valued at $762,000 after buying an additional 18,486 shares during the period. SG Americas Securities LLC acquired a new stake in Artivion during the 3rd quarter valued at approximately $450,000. Perceptive Advisors LLC grew its stake in Artivion by 4.7% during the 2nd quarter. Perceptive Advisors LLC now owns 2,793,703 shares of the company’s stock valued at $71,658,000 after purchasing an additional 124,725 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in Artivion by 3.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,301 shares of the company’s stock valued at $392,000 after purchasing an additional 481 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in Artivion during the 2nd quarter valued at approximately $366,000. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on AORT shares. Needham & Company LLC restated a “buy” rating and set a $30.00 price objective on shares of Artivion in a research note on Friday, September 27th. Stifel Nicolaus raised their price objective on Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, September 13th. JMP Securities initiated coverage on Artivion in a research note on Wednesday, October 23rd. They set an “outperform” rating and a $33.00 price objective for the company. Finally, Oppenheimer lifted their target price on Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $31.00.

Insider Transactions at Artivion

In related news, SVP Jean F. Holloway sold 3,167 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $26.55, for a total value of $84,083.85. Following the sale, the senior vice president now owns 161,932 shares of the company’s stock, valued at approximately $4,299,294.60. This trade represents a 1.92 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Amy Horton sold 12,430 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total value of $325,417.40. Following the completion of the sale, the chief accounting officer now directly owns 139,989 shares in the company, valued at approximately $3,664,912.02. This trade represents a 8.16 % decrease in their position. The disclosure for this sale can be found here. Insiders own 8.10% of the company’s stock.

Artivion Price Performance

Shares of AORT opened at $26.65 on Friday. The firm has a market cap of $1.12 billion, a price-to-earnings ratio of -1,332.50 and a beta of 1.75. The stock has a 50 day moving average of $26.31 and a 200-day moving average of $25.32. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71. Artivion, Inc. has a 52 week low of $13.42 and a 52 week high of $30.00.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.